Targacept Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 60

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $95.5M

  • Investors
  • 1

Targacept General Information

Description

Developer of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. The company develops a product for treating Alzheimer's disease, Parkinson's disease, Lewy body dementia, ulcerative colitis, depression, pain, anxiety disorders and schizophrenia.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 100 North Main Street
  • Suite 1510
  • Winston-Salem, NC 27101
  • United States
Primary Industry
Biotechnology
Acquirer
Gyre Therapeutics
Vertical(s)
Life Sciences
Corporate Office
  • 100 North Main Street
  • Suite 1510
  • Winston-Salem, NC 27101
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Targacept Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 20-Aug-2015 $95.5M Completed Profitable
8. 2PO 19-May-2011 Completed Profitable
7. 2PO 07-Oct-2009 Completed Profitable
6. IPO 11-Apr-2006 Completed Profitable
5. Convertible Debt 21-Dec-2004 Completed Generating Revenue
4. Later Stage VC (Series C) 06-Dec-2004 Completed Profitable
3. Later Stage VC (Series C) 19-Mar-2003 Completed Profitable
2. Later Stage VC (Series C) 10-Dec-2002 $45.7M $99M Completed Profitable
1. Early Stage VC (Series A) 01-Aug-2000 $53.6M $53.6M Completed Generating Revenue
To view Targacept’s complete valuation and funding history, request access »

Targacept Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A 5,000,000 $0.001000 $4.65 $4.65 1x $4.65 5.18%
To view Targacept’s complete cap table history, request access »

Targacept Board Members (8)

Name Representing Role Since
Alan Dunton MD Self Board Member
Charles Blixt JD Self Board Member
Errol De Souza Ph.D Self Board Member
Julia Brown Self Board Member and Compensation Committee Chair
You’re viewing 4 of 8 board members. Get the full list »

Targacept Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Targacept Former Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Academy Venture Fund Venture Capital Minority
Advent Life Sciences Venture Capital Minority
Advent Venture Partners Venture Capital Minority
Auriga Partners (Paris) Venture Capital Minority
Aventis Corporation Minority
You’re viewing 5 of 21 investors. Get the full list »

Targacept Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gyre Therapeutics 20-Aug-2015 Drug Discovery
To view Targacept’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Targacept FAQs

  • When was Targacept founded?

    Targacept was founded in 1997.

  • Where is Targacept headquartered?

    Targacept is headquartered in Winston-Salem, NC.

  • What is the size of Targacept?

    Targacept has 60 total employees.

  • What industry is Targacept in?

    Targacept’s primary industry is Biotechnology.

  • Is Targacept a private or public company?

    Targacept is a Private company.

  • What is the current valuation of Targacept?

    The current valuation of Targacept is .

  • What is Targacept’s current revenue?

    The current revenue for Targacept is .

  • How much funding has Targacept raised over time?

    Targacept has raised $316M.

  • Who are Targacept’s investors?

    Academy Venture Fund, Advent Life Sciences, Advent Venture Partners, Auriga Partners (Paris), and Aventis are 5 of 21 investors who have invested in Targacept.

  • When was Targacept acquired?

    Targacept was acquired on 20-Aug-2015.

  • Who acquired Targacept?

    Targacept was acquired by Gyre Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »